In preparing to launch a rare-disease medication, it is important to understand the needs in the therapy area and invest strategically to maximize the impact on the unique rare-disease environment.
Emmanuel Aisabokhae, Ben Enejo, Thomas F. Unger
Advertisement
By Emmanuel Aisabokhae, MPharm; Ben Enejo, MBA; and Thomas F. Unger, PhD. at Arthur D. Little
Articles by Emmanuel Aisabokhae, Ben Enejo, Thomas F. Unger
Advertisement
Latest Updated Articles
Maximizing the Chance of Launch Success with Orphan DrugsPublished: February 11th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
2
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
3
Is FDA Streamlining Regulations in the Biosimilar Space?
4
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
5
